Precision BioSciences welcomes Shalini Sharp to its Board of Directors

– USA, NC –  Precision BioSciences, a genome editing company dedicated to improving life, announced today that industry veteran Shalini Sharp has joined the company’s Board of Directors.

An established business leader in the life sciences industry, Sharp is the Chief Financial Officer and Executive Vice President of Ultragenyx Pharmaceutical. Sharp brings a wealth of experience in financial management and corporate strategy in rare disease, gene therapy and oncology.

“We are thrilled to welcome Shalini Sharp to the Precision BioSciences Board of Directors,” said Precision CEO Matt Kane. “Shalini’s broad understanding of the financial markets within rare disease and oncology will be invaluable as Precision progresses into clinical trials of its genome-edited product portfolio.”

About Shalini Sharp

As CFO of Ultragenyx, a pharmaceutical company creating therapies for rare diseases, Sharp leads corporate finance, strategy and information technology. She previously served as CFO and board member of Agenus, a biotechnology company focused on cancer immunotherapies. Before that, she worked in corporate strategy at Elan Pharmaceuticals, in management consulting at McKinsey & Company and in investment banking at Goldman Sachs, always in the pharmaceutical and medical device space. Sharp holds a BA and an MBA from Harvard University. An experienced corporate leader, she is also a board member at Sutro Biopharma and Array Biopharma.

“I am excited to work with Precision as the company develops new therapies based on its next generation gene editing technology, ARCUS, which has the potential to help patients achieve better outcomes,” said Sharp. “I have also been impressed by the scaled manufacturing process Precision has developed, which is a critical and sometimes overlooked factor.”

About Precision BioSciences

Precision BioSciences is dedicated to improving life. Our mission is to cure genetic disease, overcome cancer, and feed the planet. We are striving to achieve this goal with ARCUS, our therapeutic-grade, naturally-derived genome editing platform, to help overcome life’s greatest genetic challenges.

For more information :

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.